Drug Type Biosimilar, Monoclonal antibody |
Synonyms Infliximab (geneticalrecombination) |
Target |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (04 Jul 2014), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ankylosing Spondylitis | JP | 01 Oct 2020 | |
Behcet's uveitis | JP | 01 Apr 2020 | |
Arthritis, Psoriatic | JP | 22 Jul 2015 | |
Erythrodermic psoriasis | JP | 22 Jul 2015 | |
Psoriasis vulgaris | JP | 22 Jul 2015 | |
Pustular psoriasis | JP | 22 Jul 2015 | |
Colitis, Ulcerative | JP | 04 Jul 2014 | |
Crohn Disease | JP | 04 Jul 2014 | |
Rheumatoid Arthritis | JP | 04 Jul 2014 |